Sanofi engages in the research, production, and distribution of pharmaceutical products. The company is headquartered in Paris, Ile-De-France and currently employs 84,587 full-time employees. The company went IPO on 2002-07-01. The firm focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.
Follow-Up Questions
¿Quién es el CEO de Sanofi SA?
Mr. Paul Hudson es el Chief Executive Officer de Sanofi SA, se unió a la empresa desde 2019.
¿Qué tal es el rendimiento del precio de la acción SNYNF?
El precio actual de SNYNF es de $97.15, ha decreased un 0% en el último día de negociación.
¿Cuáles son los temas de negocio principales o las industrias de Sanofi SA?
Sanofi SA pertenece a la industria Pharmaceuticals y el sector es Health Care
¿Cuál es la capitalización bursátil de Sanofi SA?
La capitalización bursátil actual de Sanofi SA es $118.3B
¿Es Sanofi SA una compra, una venta o una posición de mantener?
Según los analistas de Wall Street, 29 analistas han realizado calificaciones de análisis para Sanofi SA, incluyendo 9 fuerte compra, 12 compra, 7 mantener, 1 venta, y 9 fuerte venta
